Pay in 4 interest-free payments of $5.10 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Fellow pharma powerhouse Roche has also jumped into the oral obesity arena with the $2.7 billion acquisition of Carmot Therapeutics in December 2023, giving it access to CT-388 and CT-868, both of which are dual agonists of the GLP-1 and GIP receptors with best-in-class potential for obesity, Roche said at the time
Email us for approval
Now, I know that sounds crazy
If your region restricts import, check local customs rules before ordering and confirm cold-chain refrigerated delivery is available to your address
US$ 23.22
US$ 23.33
US$ 21.69
US$ 29.82
